Skip to main content
Premium Trial:

Request an Annual Quote

Startup Xagenic Receives $1.1M to Commercialize Chip-based MDx Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian startup Xagenic today announced it has been awarded C$1 million (US$1.1 million) by the Ontario Ministry of Research and Innovation (MRI), which the company will use to commercial its chip-based molecular diagnostic technology.

The Toronto-based company will use the funding, made through MRI's Investment Accelerator Fund-Life Sciences program, to bring to market its technology built on nanostructured microelectrodes to create highly sensitive nucleic acid sensors that detect DNA and RNA "at record-breaking speed," according to Xagenic.

In a statement, the company said that while existing molecular-based tests are complex, time-consuming, and require skilled laboratory technicians, its technology, developed at the University of Toronto, can detect pathogens in less than 30 minutes. As a result pathogen detection can be done in a doctor's office or by a patient's bedside.

Xagenic was founded a year ago and including today's announced funding has secured more than C$2.2 million in investments. Investors in the firm include Canadian technology commercialization agent Mars Innovation, the Ontario Institute for Cancer Research, the Ontario Centre of Excellence, and the Health Technology Exchange.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.